# OnCo record nct07729956 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07729956/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07729956", "NCT07729956" ;
  schema:name "A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera"@en ;
  schema:description "A phase 3 trial of izalontamab brengitecan and nab-paclitaxel in triple-negative breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07729956/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07729956> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "tnbc-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc-early/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/nab-paclitaxel/> .